An observational study in Intracranial Aneurysm, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Xuanwu Hospital, Beijing · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.
Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 20th largest by planned enrollment of the 51 observational ones that give a count, is one of 9 that started in 2026, is one of 51 observational ones, reaches primary completion later than 33 of the 41 other live ones, and was the 95th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:
Henan Provincial People's Hospital · Sites in China
Ages 18–75
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–75
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 22–80
Duan Chuanzhi · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 9
First in 2005; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Median enrollment 188 across the 49 interventional studies, 600 across the 51 observational. Of the 27 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 100 have an industry lead sponsor. The 10 most frequent:
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
Xuanwu Hospital, Beijing has 6 studies filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
7 of the studies in Intracranial Aneurysm with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06943729Huashan HospitalClinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms | 2026-12-30 |
| NCT06364293Beijing Tiantan HospitalAn Early Warning Model of Unfavorable Outcomes Following Endovascular Interventional Treatment of Intracranial Aneurysm | 2026-12-31 |
| NCT07089862Beijing Tiantan HospitalINdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) | 2026-12-31 |
| NCT07674004Henan Provincial People's HospitalSurface-Modified Flow Diverter for Intracranial Aneurysms: Assessment of Ischemic and Clinical Outcomes | 2027-02-28 |
| NCT07707076Nanfang Hospital, Southern Medical UniversityFlow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 100 studies in Intracranial Aneurysm with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We designed the Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment (WEB-RWS), an ambidirectional, multicenter, post-market real-world study with a prospective active surveillance component. The study will include patients with IAs treated with commercially available WEB devices under the direction of treating physicians in routine clinical practice. Clinical, procedural, imaging, and safety data will be collected using a standardized electronic data capture system, with safety events adjudicated by an independent clinical events committee and imaging outcomes assessed by an independent core laboratory. The primary objective is to evaluate 12-month adequate aneurysm occlusion and major adverse events after WEB treatment. The study is expected to provide comprehensive post-market evidence on the real-world performance of the WEB device in China, including its safety, effectiveness, clinical appropriateness, and health economic value in routine neurointerventional practice.
Intracranial aneurysms are abnormal dilatations of blood vessels in the brain. If an aneurysm ruptures, it can cause subarachnoid hemorrhage, which may lead to serious disability or death. Endovascular treatment has become an important treatment option for intracranial aneurysms. The Woven EndoBridge (WEB) device is an intrasaccular flow disruption device designed to treat selected intracranial aneurysms from within the aneurysm sac.
This study is a post-market, ambispective, multicenter, real-world registry study. It will evaluate the safety and performance of commercially available MicroVention WEB devices when used by treating physicians according to routine clinical practice and the approved instructions for use. The study does not assign participants to a treatment group and does not require a randomized comparison. Treatment decisions are made by the treating physicians based on standard medical care.
The study plans to enroll up to 1,000 patients from multiple study centers in China. Approximately 200 patients will be included retrospectively, and approximately 800 patients will be included prospectively. Eligible participants are patients with intracranial aneurysms treated with a commercially available WEB device. For the prospective cohort, written informed consent will be obtained from the participant or legally authorized representative before study-related data collection, as applicable.
Clinical data will be collected using an electronic data capture system. Imaging data will be de-identified and submitted for independent core laboratory assessment. Follow-up assessments are planned after the procedure and at approximately 30 days, 6 months, and 12 months. Follow-up may include neurological assessment, imaging evaluation, information on aneurysm retreatment, adverse event assessment, serious adverse event assessment, and information on antiplatelet or anticoagulant medication use.
The primary effectiveness outcome is the proportion of aneurysms with adequate occlusion at 12 months, based on the Raymond-Roy Occlusion Classification. Adequate occlusion is defined as Raymond-Roy class I or II. The primary safety outcome is the rate of major adverse events, including unexpected death or major stroke within 30 days after the procedure, and neurological death or major stroke from 31 days to 1 year after the procedure.
Other outcomes include aneurysm occlusion based on the WEB Occlusion Scale, aneurysm recurrence, aneurysm retreatment, rebleeding, parent artery patency, clinical outcome measured by the modified Rankin Scale, device-related serious adverse events, procedure-related serious adverse events, neurological events, successful device implantation and health economic outcomes. The study will mainly use descriptive statistical methods to summarize outcomes and confidence intervals.
The study population includes patients with intracranial aneurysms who are treated with the commercially available MicroVention Woven EndoBridge device as part of routine clinical care at participating study centers in China. The registry includes both retrospectively identified patients and prospectively enrolled patients. Clinical, procedural, imaging, and safety data will be collected according to the study protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Retrospective Cohort:
Prospective Cohort:
Exclusion Criteria:
Retrospective Cohort:
Prospective Cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with intracranial aneurysms who are treated with the commercially available MicroVention Woven EndoBridge device as part of routine clinical care. This cohort includes both retrospectively identified patients and prospectively enrolled patients. Clinical, procedural, imaging, safety, effectiveness, clinical appropriateness, and health economic outcomes will be collected according to the study protocol.
Device: Intrasaccular Flow Disruption Device
The intervention of interest is treatment of intracranial aneurysms using the commercially available MicroVention Woven EndoBridge device. The device is an intrasaccular flow disruption device used during endovascular treatment according to routine clinical practice and the approved instructions for use. Treatment decisions and procedural details are determined by the treating physician.
Also known as: Woven EndoBridge, WEB Device, MicroVention WEB Device, Woven EndoBridge Aneurysm Embolization System
Incidence of Major Adverse Events
Major adverse events include unexpected death or major stroke within 30 days after the procedure, and neurological death or major stroke from 31 days to 1 year after the procedure. Major stroke is defined as an ischemic or hemorrhagic stroke associated with an increase of more than 4 points in the NIHSS score.
Time frame: Up to 1 Year After the Index Procedure
Proportion of Aneurysms With Adequate Occlusion Based on Raymond-Roy Occlusion Classification
Adequate aneurysm occlusion is defined as Raymond-Roy Occlusion Classification class I or II at the 12-month follow-up. Class I indicates complete occlusion, and class II indicates residual neck without contrast filling of the aneurysm sac.
Time frame: 12 Months After the Index Procedure
Proportion of Aneurysms With Adequate Occlusion Based on WEB Occlusion Scale
Adequate aneurysm occlusion will be assessed by an independent imaging core laboratory using the Woven EndoBridge Occlusion Scale. The Woven EndoBridge Occlusion Scale is a categorical angiographic scale ranging from Class A to Class D: Class A indicates complete occlusion, Class B indicates complete occlusion with recess filling, Class C indicates neck remnant, and Class D indicates aneurysm remnant. Adequate occlusion is defined as Class A, Class B, or Class C. Class D indicates inadequate occlusion. This is a categorical scale; higher or lower numerical scores are not applicable.
Time frame: 12 Months After the Index Procedure
Aneurysm Occlusion Status Based on Raymond-Roy Occlusion Classification and WEB Occlusion Scale
Aneurysm occlusion status will be assessed by an independent imaging core laboratory using the Raymond-Roy Occlusion Classification and the Woven EndoBridge Occlusion Scale. The Raymond-Roy Occlusion Classification is a categorical angiographic classification ranging from Class I to Class III: Class I indicates complete occlusion, Class II indicates residual neck, and Class III indicates residual aneurysm. The Woven EndoBridge Occlusion Scale is a categorical angiographic scale ranging from Class A to Class D: Class A indicates complete occlusion, Class B indicates complete occlusion with recess filling, Class C indicates neck remnant, and Class D indicates aneurysm remnant. These are categorical scales; higher or lower numerical scores are not applicable.
Time frame: 12 Months After the Index Procedure
Aneurysm Occlusion Without Rebleeding in Ruptured Aneurysms
In participants with ruptured aneurysms, aneurysm occlusion status will be assessed together with the absence of rebleeding.
Time frame: 12 Months After the Index Procedure
Aneurysm Occlusion Without Rebleeding or Retreatment in Aneurysms With Residual Filling
In aneurysms with residual filling, occlusion status will be assessed together with absence of rebleeding in ruptured aneurysms or absence of retreatment.
Time frame: 12 Months After the Index Procedure
Stability of Aneurysm Occlusion
Occlusion stability will be assessed by comparing imaging results between the 6-month and 12-month follow-up visits and classified as unchanged, improved, or worsened.
Time frame: From 6 Months to 12 Months After the Index Procedure
Aneurysm Recurrence
Aneurysm recurrence is defined as aneurysm growth or recanalization within 1 year after the index procedure.
Time frame: Up to 1 Year After the Index Procedure
Aneurysm Retreatment
The proportion of participants who undergo retreatment of the target aneurysm within 1 year will be assessed.
Time frame: Up to 1 Year After the Index Procedure
Unplanned Retreatment or Alternative Treatment
The proportion of participants who undergo unplanned retreatment or alternative treatment due to aneurysm recurrence or residual aneurysm will be assessed.
Time frame: Up to 1 Year After the Index Procedure
Rebleeding Within 30 Days in Ruptured Aneurysms
In participants with ruptured aneurysms, rebleeding within 30 days after the procedure will be assessed, excluding intraprocedural rupture or bleeding.
Time frame: Up to 30 Days After the Index Procedure
Rebleeding Within 1 Year in Ruptured Aneurysms
In participants with ruptured aneurysms, rebleeding within 1 year after the procedure will be assessed, excluding intraprocedural rupture or bleeding.
Time frame: Up to 1 Year After the Index Procedure
New Bleeding of the Target Aneurysm in Unruptured Aneurysms
In participants with unruptured aneurysms, new bleeding of the target aneurysm within 1 year will be assessed, excluding intraprocedural rupture or bleeding.
Time frame: Up to 1 Year After the Index Procedure
Parent Artery Patency
Parent artery patency will be assessed at 1 year, defined as less than 50% stenosis of the parent artery or absence of clinical symptoms.
Time frame: 12 Months After the Index Procedure
Clinical Outcome Measured by Modified Rankin Scale
Clinical outcome will be assessed using the Modified Rankin Scale (mRS). The Modified Rankin Scale is an ordinal scale ranging from 0 to 6, where 0 indicates no symptoms, 5 indicates severe disability, and 6 indicates death. Higher scores indicate worse functional outcome.
Time frame: 30 Days, 6 Months, and 12 Months After the Index Procedure
Device-Related Serious Adverse Events
Serious adverse events related to the study device will be collected and summarized.
Time frame: Up to 1 Year After the Index Procedure
Procedure-Related Serious Adverse Events
Serious adverse events related to the procedure will be collected and summarized.
Time frame: Up to 1 Year After the Index Procedure
Device- or Procedure-Related Adverse Events
Periprocedural and postprocedural adverse events related to the device or procedure will be collected and summarized.
Time frame: Up to 1 Year After the Index Procedure
Neurological Events
Neurological events will include ischemic stroke, hemorrhagic stroke, neurological death, intracerebral hemorrhage, subarachnoid hemorrhage, arterial thrombosis, parent artery or branch artery perforation or rupture, and transient ischemic attack.
Time frame: Up to 1 Year After the Index Procedure
Proportion of Target Aneurysms With Successful Woven EndoBridge Device Implantation
Successful device implantation will be assessed using the procedure record and electronic case report form. Successful Woven EndoBridge device implantation is defined as successful deployment and detachment of the Woven EndoBridge device in the target aneurysm during the index procedure. The outcome will be reported as the proportion of target aneurysms with successful device implantation among target aneurysms in which Woven EndoBridge device implantation was attempted. Reasons for unsuccessful implantation, such as inappropriate device size or model, unsuitable target aneurysm anatomy, unfavorable angle, vascular tortuosity preventing access to the lesion, or other reasons, will be recorded when applicable.
Time frame: During the Index Procedure
Healthcare resource utilization
Healthcare resource utilization will be assessed by collecting data on procedure-related and follow-up medical resource use, including length of hospital stay, intensive care unit admission, additional procedures or retreatment, rehospitalization, emergency visits, outpatient visits, imaging examinations, and other aneurysm treatment-related healthcare services.
Time frame: From the index procedure through 12 months after treatment
Health-related quality of life
Health-related quality of life will be assessed using protocol-specified patient-reported quality-of-life instruments. Changes in health-related quality-of-life scores from baseline to follow-up will be evaluated.
Time frame: Baseline and 12 months after treatment
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.
Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 24 months is below that.
Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.